These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31154671)

  • 21. Understanding the reasons for provincial discordance in cancer drug funding-a survey of policymakers.
    Srikanthan A; Penner N; Chan KKW; Sabharwal M; Grill A
    Curr Oncol; 2018 Aug; 25(4):257-261. PubMed ID: 30111966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
    Meyers DE; Jenei K; Chisamore TM; Gyawali B
    JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations.
    Binder L; Ghadban M; Sit C; Barnard K
    Curr Oncol; 2022 Mar; 29(3):1514-1526. PubMed ID: 35323327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy.
    Bentley C; Peacock S; Abelson J; Burgess MM; Demers-Payette O; Longstaff H; Tripp L; Lavis JN; Wilson MG
    Health Res Policy Syst; 2019 Feb; 17(1):17. PubMed ID: 30732616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Examining the association between oncology drug clinical benefit and the time to public reimbursement.
    Thomson S; Everest L; Witzke N; Jiao T; Delos Santos S; Nguyen V; Cheung MC; Chan KKW
    Cancer Med; 2022 Jan; 11(2):380-391. PubMed ID: 34850587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canadian Contraception Consensus (Part 1 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N;
    J Obstet Gynaecol Can; 2015 Oct; 37(10):936-42. PubMed ID: 26606712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canadian Contraception Consensus (Part 2 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
    J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value assessment of oncology drugs using a weighted criterion-based approach.
    Ezeife DA; Dionne F; Fares AF; Cusano ELR; Fazelzad R; Ng W; Husereau D; Ali F; Sit C; Stein B; Law JH; Le L; Ellis PM; Berry S; Peacock S; Mitton C; Earle CC; Chan KKW; Leighl NB
    Cancer; 2020 Apr; 126(7):1530-1540. PubMed ID: 31860138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.
    Lexchin J
    BMJ Open; 2017 Oct; 7(10):e018372. PubMed ID: 29061631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations.
    Jenei K; Meyers DE
    BMJ Open; 2023 Oct; 13(10):e066378. PubMed ID: 37844982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of pricing strategy on the costs of oral anti-cancer drugs.
    Truong J; Chan KKW; Mai H; Chambers A; Sabharwal M; Trudeau ME; Cheung MC
    Cancer Med; 2019 Jul; 8(8):3770-3781. PubMed ID: 31132223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
    Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
    CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meaningful patient representation informing Canada's cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review.
    Hoch JS; Brown MB; McMahon C; Nanson J; Rozmovits L
    Curr Oncol; 2014 Oct; 21(5):263-6. PubMed ID: 25302034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Pathway for New Cancer Drug Access in Canada.
    Gotfrit J; Dempster W; Chambers J; Wheatley-Price P
    Curr Oncol; 2022 Jan; 29(2):455-464. PubMed ID: 35200541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of drug reimbursement in Canada: the Pan-Canadian Pharmaceutical Alliance for new drugs.
    Husereau D; Dempster W; Blanchard A; Chambers J
    Value Health; 2014 Dec; 17(8):888-94. PubMed ID: 25498784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of a novel prioritization framework on clinician-led oncology drug submissions.
    Keech J; Beca J; Eisen A; Kennedy E; Kim J; Kouroukis CT; Darling G; Ferguson SE; Finelli A; Petrella TM; Perry JR; Chan K; Gavura S
    Curr Oncol; 2019 Apr; 26(2):e155-e161. PubMed ID: 31043821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada.
    Nagase FNI; Stafinski T; Sun J; Jhangri G; Menon D
    Orphanet J Rare Dis; 2019 Jun; 14(1):127. PubMed ID: 31174574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.